ICER asks for comments on Vertex CF drug prices

1 October 2019
money_drugs_scales_large-1-

The US Institute for Clinical and Economic Review (ICER) has posted a draft scoping document on its planned review of the cost-effectiveness offered by Vertex Pharmaceuticals’ (Nasdaq: VRTX) cystic fibrosis (CF) drugs in the USA.

In its review, The ICER will consider the triple combination therapy elexacaftor/tezacaftor/ivacaftor, which is currently under review by the US Food and Drug Administration, to estimate what would be a fair price in light of data on clinical effectiveness.

The cost-effectiveness body will also examine new data that has become available since its May 2018 review of Symdeko (tezacaftor/ivacaftor), Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology